Role of thiamine in Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 26, Issue 8, 2011, Pages 588-598

  Vinh Quc Lu'O'Ng, Khanh ^a   Nguyen, Lan Thi Hoàng ^a  

^a Vietnamese American Medical Research Foundation   (United States)

Author keywords

Alzheimer's disease; dementia; thiamine; vitamin B1

Indexed keywords

ACETYLCHOLINE; ALKALINE PHOSPHATASE; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN E; BENFOTIAMINE; CHOLINESTERASE INHIBITOR; CYTOSOLIC TRANSKETOLASE; FURSULTIAMINE; GLUCOSE; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; HISTAMINE; MESSENGER RNA; NEUROTRANSMITTER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NORADRENALIN; OXOGLUTARATE DEHYDROGENASE; PROTEIN P53; PYRUVATE DEHYDROGENASE COMPLEX; SULBUTIAMINE; THIAMINE; THIAMINE PYROPHOSPHATASE; TRANSKETOLASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BIOLOGICAL ACTIVITY; BRAIN ATROPHY; COGNITION; DNA DAMAGE; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME SYNTHESIS; GASTROINTESTINAL ABSORPTION; GENE EXPRESSION; GENETIC DISORDER; GENOTYPE; GLUCOSE METABOLISM; HUMAN; KIDNEY CLEARANCE; LOCUS CERULEUS; MINI MENTAL STATE EXAMINATION; MUTATION; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; VITAMIN SUPPLEMENTATION; WERNICKE ENCEPHALOPATHY;

EID: 84857316382     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317511432736     Document Type: Review

References (138)

1. Siebert G, Gessner B, Klasser M Nutrition and Neurobiology. Somogyi JC Hotzel D, ed. Basel: Karger ; 1986: 1-26.
2. Martin P, Singleton CK, Hiller-Stumhöfel S. The role of thiamine deficiency in alcoholic brain disease. Alcohol Res Health. 2003 ; 27 (2). 174-181
3. Ishii K, Sarai K, Sanemori H, Kawasaki T. Concentration of thiamine and its phosphate esters in rat tissues determined by high pressure liquid chromography. J Nutr Sci Vitaminol (Tokyo). 1979 ; 25 (6). 517-523
4. Bubber P, Ke ZJ, Gibson GE. Tricarboxylic acid cycle enzymes following thiamine deficiency. Neurochem Int. 2004 ; 45 (7). 1021-1028 (Pubitemid 39164927)
5. Mastrogiacomo F, Bergeron C, Kish SJ. Brain α-ketoglutarate dehydrogenases complexes activity in Alzheimer's disease. J Neurochem. 1993 ; 61 (6). 2007-2014
6. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology. 1999 ; 53 (9). 1937-1942
7. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes?. Altern Med Rev. 2009 ; 14 (4). 373-379
8. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA. 2010 ; 107 (15). 7036-7041
9. Saito N, Kimura M, Kuchiba A, Itokawa Y. Blood thiamine levels in outpatients with diabetes mellitus. J Nutr Sci Vitaminol. 1987 ; 33 (6). 421-430
10. Kjøsen BMS, Seim SH. The transketolase assay of thiamine in some diseases. Am J Clin Nutr. 1977 ; 30 (10). 1591-1596 (Pubitemid 8205346)
11. Thornalley PJ, Babaei-Jadidi R, Al Ali H, et al. High prevalence of low thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia. 2007 ; 50 (10). 2164-2170 (Pubitemid 47373853)
12. Glasø M, Nordbø G, Diep L, Bøhmer T. Reduced concentrations of several vitamins in normal weight patients with late-onset dementia of the Alzheimer type without vascular disease. J Nutr Health Aging. 2004 ; 8 (5). 407-413 (Pubitemid 39294654)
13. Gold M, Chen MF, Johnson K. Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer's type. Arch Neurol. 1995 ; 52 (11). 1081-1086
14. Molina JA, Jiménez-Jiménez FJ, Hernánz A, et al. Cerebrospinal fluid levels of thiamine in patients with Alzheimer's disease. J Neural Transm. 2002 ; 109 (7-8). 1035-1044 (Pubitemid 34762342)
15. Gibson GE, Sheu KF, Blass JP, et al. Reduced activities of thiamine-dependent enzymesin the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol. 1988 ; 45 (8). 836-840
16. Sheu KF, Clarke DD, Kim YT, Harding BJ, DeCicco J. Studies of transketolase abnormality in Alzheimer's disease. Arch Neurol. 1988 ; 45 (8). 841-845
17. Paoletti F, Mocali A, Marchi M, Sorbi S, Piacentini S. Occurrence of transketolase abnormalities in extracts of forskin fibroblasts from patients with Alzheimer's disease. Biochem Biophys Res Commun. 1990 ; 172 (2). 396-401 (Pubitemid 20384434)
18. Tombaccini D, Mocali A, Paoletti F. Characteristic transketolase alterations in dermal fibroblasts of Alzheimer patients are modulated by culture conditions. Exp Mol Pathol. 1994 ; 60 (2). 140-146 (Pubitemid 24287210)
19. Paoletti F, Mocali A, Tombaccini D. Cysteine proteinases are responsible for characteristic transketolase alterations in Alzheimer fibroblasts. J Cell Physiol. 1997 ; 172 (1). 63-68 (Pubitemid 27283348)
20. Martin PR, McCool BA, Singleton CK. Molecular genetics of transketolase in the pathogenesis of the Wernicke-Korsakoff syndrome. Metab Brain Dis. 1995 ; 10 (1). 45-55
21. Blass JP, Gibson GE. Abnormality of a thiamine-requiring enzyme in patients with Wernicke-Korsakoff syndrome. N Engl J Med. 1977 ; 297 (25). 1367-1370 (Pubitemid 8256294)
22. Mukherjee AB, Svoronos S, Ghazanfari A, et al. Transketolase abnormality in cultured fibroblasts from familial chronic alcoholic men and their male offspring. J Clin Invest. 1987 ; 79 (4). 1039-1043 (Pubitemid 17065480)
23. Heap LC, Pratt OE, Ward RJ, et al. Individual susceptibility to Wernicke-Korsakoff syndrome and alcoholism-induced cognitive deficit: impaired thiamine utilization found in alcoholics and alcohol abusers. Psychiatr Genet. 2002 ; 12 (4). 217-224 (Pubitemid 36026931)
24. Licastro F, Chiappelli M, Thal LJ, Masliah E.. α-1-antichymotrypsin polymorphism in the gene promoter region affects survival and synapsis loss in Alzheimer's disease. Arch Gerontol Geriatr Suppl. 2004 ; (9). 243-251 (Pubitemid 38822874)
25. Lane RM, Farlow MR. Lipid homeostatis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res. 2005 ; 46 (5). 949-968
26. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003 ; 118 (1-2). 140-146 (Pubitemid 37238996)
27. Thal DR, Papassotiropoulos A, Saido TC, et al. Capillary cerebral amyloid angiopathy identifies a distinct APOE 4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol. 2010 ; 120 (2). 169-183
28. Wolk DA, Dickerson BC. Alzheimer's disease neuroimaging initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. PNAS. 2010 ; 107 (22). 10256-10261
29. Paz-y-Miño C, Carrera C, López-Cortés A, et al. Genetic polymorphisms in apolipoprotein E and glutathione peroxidase 1 genes in the Ecuadorian population affected with Alzheimer's disease. Am J Med Sci. 2010 ; 340 (5). 373-377
30. Muramatsu T, Kato M, Matsui T, et al. Apolipoprotein E 4 allele distribution in Wernicke-Korsakoff syndrome with or without global intellectual deficits. J Neural Transm. 1997 ; 104 (8-9). 913-920 (Pubitemid 27510220)
31. Song F, Poljak A, Smythe GA, Sachdev P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev. 2009 ; 61 (2). 69-80
32. Nielsen HM, Minthon L, Londos E, et al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology. 2007 ; 69 (16). 1569-1579 (Pubitemid 350287140)
33. Schmechel DE, Browndyke J, Ghio A. Strategies for dissecting genetic-environmental interactions in neurodegenerative disorders. Neurotoxicology. 2006 ; 27 (5). 637-657 (Pubitemid 44232993)
34. Schmechel DE. Art, α-1-antitrypsin polymorphisms and intense creative energy: blessing or curse?. Neurotoxicology. 2007 ; 28 (5). 899-914
35. Jacobia SJ, Korotchkina LG, Patel MS. Characterization of a missense mutation at histidine-44 in a pyruvate dehydrogenase-deficient patient. Biochim Biophys Acta. 2002 ; 1586 (1). 32-42 (Pubitemid 34066614)
36. Naito E, Ito M, Takeda E, Yokota I, Yoshijima S, Kuroda Y. Molecular analysis of abnormal pyruvate dehydrogenase in a patient with thiamine-responsive congenital lactic academia. Pediatr Res. 1994 ; 36 (3). 340-346 (Pubitemid 24256782)
37. Naito E, Ito M, Yokota I, et al. Thiamine-responsive pyruvate dehydrogenase deficiency in two patients caused by a point mutation (F205L and L216F) within the thiamine pyrophosphate pyrophosphate binding region. Biochim Biophys Acta. 2002 ; 1588 (1). 79-84
38. Bonne G, Benelli C, De Meirleir L, et al. E1 pyruvate dehydrogenase deficiency in a child with motor neuropathy. Pediatr Res. 1993 ; 33 (3). 284-288 (Pubitemid 23101843)
39. Meléndez RR. Importance of water-soluble vitamins as regulatory factors of genetic expression [in Spanish]. Rev Invest Clin. 2002 ; 54 (1). 77-83
40. Ko LJ. Prives C. p53: puzzle and paradigm. Genes Dev. 1996 ; 10 (9). 1054-1072
41. Lanni C, Racchi M, Mazzini G, et al. Conformationally altered p53: a novel Alzheimer's disease marker?. Mol Psychiatry. 2008 ; 13 (6). 641-647 (Pubitemid 351704936)
42. Uberti D, Lanni C, Carsana T, et al. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol Aging. 2006 ; 27 (9). 1193-1201 (Pubitemid 44067307)
43. McLure KG, Takagi M, Kastan MB. NAD+ modulates p53 DNA binding specificity and function. Mol Cellular Biol. 2004 ; 24 (22). 9958-9967 (Pubitemid 39458821)
44. Proctor CJ, Gray DA. GSK3 and p53-is there a link in Alzheimer's disease?. Mol Neurodegeneration. 2010 ; 7: 5
45. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem. 2008 ; 104 (6). 1433-1439 (Pubitemid 351316776)
46. Zhao J, Sun X, Yu Z, et al. Exposure to pyrithiamine increases beta-amyloid accumulation, Tau hyperphosphorylation, and glycogen synthetase kinase-3 activity in the brain. Neurotox Res. 2010 ; 19 (4). 575-583
47. Pan X, Gong N, Zhao J, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain. 2010 ; 133 (pt 5). 1342-1351
48. Gillardon F, Skutella T, Uhlmann E, Holsboer F, Zimmermann M, Behl C. Activation of c-Fos contributes to amyloid beta-peptide-induced neurotoxicity. Brain Res. 1996 ; 706 (1). 169-172 (Pubitemid 26031109)
49. Lu W, Mi R, Tang H, Liu S, Fan M, Wang L. Over-expression of c-fos mRNA in the hippocampal neurons in Alzheimer's disease. Chin Med J (Engl). 1998 ; 111 (1). 35-37
50. Marcus DL, Strafaci JA, Miller DC, et al. Quantitative neuronal c-fos and c-jun expression in Alzheimer's disease. Neurobiol Aging. 1998 ; 19 (5). 393-400 (Pubitemid 29065488)
51. Hazell AS, Todd KG, Butterworth RF. Mechanisms of neuronal cell death in Wernicke's encephalopathy. Metab Brain Dis. 1998 ; 13 (2). 97-122 (Pubitemid 28350746)
52. Hazell AS, McGahan L, Tetzlaff WW, et al. Immediate-early gene expression in the brain of the thiamine-deficient rat. J Mol Neurosci. 1998 ; 10 (1). 1-15 (Pubitemid 28292945)
53. Zimitat C, Nixon PF. Glucose induced IEG expression in the thiamin-deficient rat brain. Brain Res. 2001 ; 892 (1). 218-227 (Pubitemid 32126585)
54. Nabokina SM, Said HM. Characterization of the 5'-regulatory region of the human thiamin transporter SLC19A3: in vitro and in vivo studies. Am J Physiol Gastrointest Liver Physiol. 2004 ; 287 (4). G822 - G829 (Pubitemid 39280440)
55. Santpere G, Nieto M, Puig B, Ferrer I. Abnormal Sp1 transcription factor expression in Alzheimer's disease and tauopathies. Neurosci Lett. 2006 ; 397 (1-2). 30-34 (Pubitemid 43340453)
56. Citron BA, Dennis JS, Zeitlin RS, Echeverrie V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J Neurosci Res. 2008 ; 86 (11). 2499-2504
57. Brock B, Basha R, DiPalma K, et al. Co-localization and distribution of cerebral APP and Sp1 and its relationship to amyloidogenesis. J Alzheimers Dis. 2008 ; 13 (1). 71-80 (Pubitemid 351365624)
58. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. Transcriptional regulation of BACE1, the β-amyloid precursor protein β-secretase, by Sp1. Mol Cell Biol. 2004 ; 24 (2). 865-874 (Pubitemid 38057936)
59. Docagne F, Gabriel C, Lebeurrier N, et al. Sp1 and Smad transcription factors co-operate to mediate TGF-β-dependent activation of amyloid-β precursor protein gene transcription. Biochem J. 2004 ; 383 (pt 2). 393-399 (Pubitemid 39446701)
60. Gatta L, Cardinale A, Wannenes F, et al. Peripheral blood mononuclear cells from mild cognitive impairment patients show deregulation of Bax and Sods1 mRNAs. Neurosci Lett. 2009 ; 453 (1). 36-40
61. Love S, Barber R, Wilcock GK. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain. 1999 ; 122 (pt 2). 247-253 (Pubitemid 29067207)
62. Kassner SS, Bonaterra GA, Kaiser E, et al. Novel systemic markers for patients with Alzheimer disease?-a pilot study. Curr Alzheimer Res. 2008 ; 5 (4). 358-366
63. Abeti R, Abramov AY. Duchen MR. β-Amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain. 2011 ; 134 (pt 6). 1658-1672
64. Infante J, Llorca J, Mateo I, et al. Interaction between poly(ADP-ribose) polymerase 1 and interleukin 1A genes is associated with Alzheimer's disease risk. Dement Geriatr Cogn Disord. 2007 ; 23 (4). 215-218 (Pubitemid 46496806)
65. Liu HP, Lin WY, Wu BT, et al. Evaluation of the poly(ADP-ribose) polymerase-1 gene variants in Alzheimer's disease. J Clin Lab Anal. 2010 ; 24 (3). 182-186
66. Shin BH, Choi SH, Cho EY, et al. Thiamine attenuates hypoxia-induced cell death in cultured neonatal rat cardiomyocytes. Mol Cells. 2004 ; 18 (2). 133-140 (Pubitemid 40081205)
67. Yadav UCS, Kalariya NM, Srivastava SK, Ramana KV. Protective role of benfotiamine, a fat soluble vitamin B1 analogue, in the liposaccharide-induced cytotoxic signals in murine macrophages. Free Radic Biol Med. 2010 ; 48 (10). 1423-1434
68. Ikegaya Y, Matsura S. Ueno S, et al. β-amyloid enhances glial glutamate uptake activity and attenuates synaptic efficacy. J Biol Chem. 2002 ; 277 (35). 32180-32186 (Pubitemid 34969032)
69. Cullen KM, Hallen GM. Neurofibrillary tangles in chronic alcoholics. Neuropathol Appl Neurobiol. 1995 ; 21 (4). 312-318
70. Calingasan NY, Gandy SE, Baker H, et al. Accumulation of amyloid precursor protein-like immunoreactivity in rat brain in response to thiamine deficiency. Brain Res. 1995 ; 677 (1). 50-60
71. Calingasan NY, Gandy SE, Baker H, et al. Novel neuritic clusters with accumulations of amyloid precursor protein and amyloid precursor-like protein 2 immunoreactivity in brain regions damaged by thiamine deficiency. Am J Pathol. 1996 ; 149 (3). 1063-1071 (Pubitemid 26334188)
72. Mandrekar-Colucci S, Landreth GE. Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2010 ; 9 (2). 156-167
73. Karuppagounder SS, Xu H, Shi Q, et al. Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol Aging. 2009 ; 30 (10). 1587-1600
74. Frederikse PH, Farnsworth P, Zigler JS. Thiamine deficiency in vivo produces fiber cell degeneration in mouse lenses. Biochem Biophys Res Commun. 1999 ; 258 (3). 703-707 (Pubitemid 29290333)
75. Hazell AS, Sheedy D, Oanea R, Aghourian M, Sun S, Jung JY, et al. Loss of astrocytic glutamate transporters in Wernicke encephalopathy. Glia. 2010 ; 58: 148-156
76. Ke ZJ, Gibson GE. Selective response of various brain cell types during neurodegeneration induced by mild impairment of oxidative metabolism. Neurochem Int. 2004 ; 45 (2-3). 361-369 (Pubitemid 38625626)
77. Todd KG, Butterworth RF. Early microglial response in experimental thiamine deficiency: an immunohistochemical analysis. Glia. 1999 ; 25 (2). 190-198 (Pubitemid 29032774)
78. Calingasan NY, Park LC, Calo LL, Trifiletti RR, Gandy SE, Gibson GE. Induction of nitric oxide synthase and microglial responses precede selective cell death induced by chronic impairment of oxidative metabolism. Am J Pathol. 1998 ; 153 (2). 599-610 (Pubitemid 28373670)
79. Francis PT, Palmer AM, Snape M, Wilcox GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999 ; 66 (2). 137-147 (Pubitemid 29103513)
80. Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem. 1983 ; 40 (2). 503-509 (Pubitemid 13195690)
81. Francis PT, Palmer AM, Sims NR, et al. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N Engl J Med. 1985 ; 313 (1). 7-11 (Pubitemid 15068737)
82. Klingner M, Apelt J, Kumar A, et al. Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with beta-amyloid plaque pathology. Int J Dev Neurosci. 2003 ; 21 (7). 357-369 (Pubitemid 37346400)
83. Tsang SW, Lai MK, Kirvell S, et al. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol Aging. 2006 ; 27 (9). 1216-1223 (Pubitemid 44088578)
84. Ruenwongsa P, Pattanavibag S. Impairment of acetylcholine synthesis in deficient rats developed by prolonged tea consumption. Life Sci. 1984 ; 34 (4). 365-370 (Pubitemid 14218306)
85. Vorhees CV, Schmidt DE, Barrett RJ. Effects of pyrithiamin on acetylcholine levels and utilization in rat brain. Brain Res Bull. 1978 ; 3 (5). 493-496 (Pubitemid 9042061)
86. Meador KJ, Nichols ME, Franke P, et al. Evidence for a central cholinergic effect of high-dose thiamine. Ann Neurol. 1993 ; 34 (5). 724-726 (Pubitemid 23333246)
87. Barclay LL, Gibson GE, Blass JP. Impairment of behavior and acetylcholine metabolism in thiamine deficiency. J Pharmacol Exp Ther. 1981 ; 217 (3). 537-543 (Pubitemid 11082234)
88. Heneka MT, Nadrigny F, Regen T, et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA. 2010 ; 107 (13). 6058-6063
89. McEntee WJ, Mair RG. Memory impairment in Korsakoff's psychosis: a correlation with brain noradrenergic activity. Science. 1978 ; 202 (4370). 905-907 (Pubitemid 9122726)
90. Mair RG, Anderson CD, Langlais PJ, McEntee WJ. Thiamine deficiency depletes cortical norepinephrine and impairs learning processes in the rat. Brain Res. 1985 ; 360 (1-2). 273-284 (Pubitemid 16171024)
91. Mousseau DD, Raghavendra Rao VL, Butterworth RF. Vesicular dysfunction during experimental thiamine deficiency is indicated by alterations in dopamine metabolism. Eur J Pharmacol. 1996 ; 317 (2-3). 263-267 (Pubitemid 27014030)
92. Oi Y, Shishido C, Wada K, Odaka H, Ikeda H, Iwai K. Allylthiamindisulfide and related compounds enhance thermogenesis with increasing noradrenaline and adrenaline secretion in rats. J Nutr Sci Vitaminol. 1999 ; 45 (5). 643-653 (Pubitemid 30002818)
93. Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science. 1991 ; 253 (5026). 1380-1386 (Pubitemid 21917285)
94. Westphalen RI, Scott HL, Dodd PR. Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer Disease. J Neural Transm. 2003 ; 110 (9). 1013-1027 (Pubitemid 37100405)
95. Baba A, Mitsumori K, Yamada MK, Nishiyama N, Matsuki N, Ikegaya Y. Beta-amyloid prevents excitotoxicity via recruitment of glial glutamate transporters. Naunyn Schmiedebergs Arch Pharmacol. 2003 ; 368 (3). 234-238 (Pubitemid 37255485)
96. Bell KF, Ducatenzeiler A, Ribeiro-da-Silva A, Duff K, Bennett DA, Cuello AC. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging. 2006 ; 27 (11). 1644-1657 (Pubitemid 44344842)
97. Jacob CP, Koutsilieri E, Bartl J, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis. 2007 ; 11 (1). 97-116 (Pubitemid 46376714)
98. Thal DR. Excitatory amino acid transporter EAAT-2 in tangle-bearing neurons in Alzheimer's disease. Brain Pathol. 2002 ; 12 (4). 405-411 (Pubitemid 35154927)
99. Scott HL, Tannenberg AE, Dodd PR. Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex. J Neurochem. 1995 ; 64 (5). 2193-2202
100. Honig LS, Chambliss DD, Bigio EH, Carroll SL, Elliott JL. Glutamate transporter EAAT2 splice variants occur not only in ASL, but also in AD and controls. Neurology. 2000 ; 55 (8). 1082-1088
101. Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol. 1997 ; 56: 901-911 (Pubitemid 27329111)
102. Scott HL, Pow DV, Tannenberg AE, Dodd PR.. Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J Neurosci. 2002 ; 22 (3). RC206
103. Masliah E, Alford M, Mallory M, Rockkenstein E, Moechars D, Van Leuven F. Abnormal transport function in mutant amyloid precursor protein transgenic mice. Exp Neurol. 2000 ; 163 (2). 381-387 (Pubitemid 30399086)
104. Zoia CP, Tagliabue E, Isella V, et al. Fibroblast glutamate transport in aging and in AD: correlations with disease severity. Neurobiol Aging. 2005 ; 26 (6). 825-832 (Pubitemid 40249484)
105. Hazell AS, Todd KG, Butterworth RF. Mechanisms of neuronal cell death in Wernicke's encephalopathy. Metab Brain Dis. 1998 ; 13 (2). 97-122 (Pubitemid 28350746)
106. Hazell AS, Pannunzio P, Rama Rao KV, Pow DV, Rambaldi A. Thiamine deficiency results in downregulation of the GLAST glutamate transporter in cultured astrocytes. Glia. 2003 ; 43 (2). 175-184 (Pubitemid 36897278)
107. Hazell AS, Sheedy D, Oanea R, et al. Loss of astrocytic glutamate transporters in Wernicke encephalopathy. Glia. 2010 ; 58 (2). 148-156
108. Hazell AS, Rao KV, Danbolt NC, Pow DV, Butterworth RF. Selective down-regulation of the astrocyte glutamate transporters GLT-1 and GLAST within the medial thalamus in experimental Wernicke's encephalopathy. J Neurochem. 2001 ; 78 (3). 560-568 (Pubitemid 32729984)
109. Cacabelos R, Yamatodani A, Niigawa H, et al. Brain histamine in Alzheimer's disease. Methods Find Exp Clin Pharmacol. 1989 ; 11 (5). 353-360 (Pubitemid 19141366)
110. Cacabelos R, Fernández-Novoa L, Pérez-Trullén JM, Franco-Maside A, Alvarez XA. Serum histamine in Alzheimer's disease and multi-infarct dementia. Methods Find Exp Clin Pharmacol. 1992 ; 14 (9). 711-715 (Pubitemid 23057191)
111. Mazurkiewicz-Kwilecki IM, Nsonwah S. Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can J Physiol Pharmacol. 1989 ; 67 (1). 75-78 (Pubitemid 19068116)
112. Panula P, Rinne J, Kuokkanen K, et al. Neuronal histamine deficit in Alzheimer's disease. Neuroscience. 1998 ; 82 (4). 993-997 (Pubitemid 27502044)
113. Medhurst AD, Atkins AR, Beresford IJ, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exper Ther. 2007 ; 321 (3). 1032-1045 (Pubitemid 46762709)
114. McRee RC, Terry-Ferguson M, Langlais PJ, et al. Increased histamine release and granulocytes within the thalamus of a rat model of Wernicke's encephalopathy. Brain Res. 2000 ; 858 (2). 227-236 (Pubitemid 30119984)
115. Onodera K, Ogura Y. Effects of histaminergic drugs on muricide induced by thiamine deficiency. Jpn J Pharmacol. 1984 ; 34 (1). 15-21 (Pubitemid 14123246)
116. Onodera K, Maeyama K, Watanabe T. Regional changes in brain histamine levels following dietary-induced thiamine deficiency in rats. Jpn J Pharmacol. 1990 ; 54: 339-343 (Pubitemid 20386421)
117. Mimori Y, Katsuoka H, Nakamura S. Thiamine therapy in Alzheimer's disease. Metab Brain Dis. 1996 ; 11 (1). 89-94 (Pubitemid 26101015)
118. Blass JP, Gleason P, Brush D, DiPonte P, Thaler H.. Thiamine and Alzheimer's disease. A pilot study. Arch Neurol. 1988 ; 45 (8). 833-835
119. Meador K, Loring D, Nichols M, et al. Preliminary findings of high-dose thiamine in dementia of Alzheimer's type. J Geriatr Psychiatry Neurol. 1993 ; 6 (4). 222-229 (Pubitemid 23302143)
120. Nolan KA, Black RS, Sheu KFR, Lanberg J, Blass JP. A trial of thiamine in Alzheimer's disease. Arch Neurol. 1991 ; 48 (1). 81-83
121. Pan X, Gong N, Zhao J, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloidprecursor protein/presenilin-1 transgenic mice. Brain. 2010 ; 133 (pt 5). 1342-1351
122. Volvert ML, Seyen S, Piette M, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. 2008 ; 8: 10
123. Bizot JC, Herpin A, Pothion S, Pirot S, Trovero F, Ollat H. Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to- sample task. Prog Neuropsychopharmacol Biol Psychiatry. 2005 ; 29 (6). 928-935 (Pubitemid 41080114)
124. Micheau J, Durkin TP, Destrade C, Rolland Y, Jaffard R. Chronic administration of sulbutiamine improves long term memory formation in mice: possible cholinergic mediation. Pharmacol Biochem Behav. 1985 ; 23 (2). 195-198 (Pubitemid 16216439)
125. Ollat H, Laurent B, Bakchine S, Michel BF, Touchon J, Dubois B. Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease [in French]. Encephale. 2007 ; 33 (2). 211-215 (Pubitemid 46787710)
126. Baum RA, Iber FL. Thiamine-the interaction of aging, alcoholism, and malabsorption in various populations. World Rev Nutr Diet. 1984 ; 44: 85-116
127. Schaller K, Holler H.. Thiamine absorption in rat. II. Intestinal alkaline phosphatase activity and thiamine absorption from rat small intestines in-vitro and in-vivo. Int J Vit Nutr Res. 1975 ; 45 (1). 30-38
128. Rindi G, Ricci V, Gastaldi G, Patrini C.. Intestinal alkaline phosphatase can transphosphorylate during intestinal transport in the rat. Arch Physiol Biochem. 1995 ; 103 (1). 33-38
129. Luong KVQ, Nguyen LTH. Adult hypophosphatasia and a low level of red blood cell thiamine pyrophosphate. Ann Nutr Metab. 2005 ; 49 (2). 107-109 (Pubitemid 40827632)
130. Detel D, Baticic L, Varljen J. The influence of age on intestinal dipeptidyl peptidase IV (DPP IV/CD26), disaccharidase, and alkaline phosphatase activities in C57BL/6 mice. Exp Aging Res. 2008 ; 34 (1). 49-62
131. Jang I, Jung K, Cho J. Influence of age on duodenal brush border membrane and specific activities of brush border membrane enzymes in Wistar rats. Exp Anim. 2000 ; 49 (4). 281-287
132. Höhn P, Gabbert H, Wagner R.. Differentiation and aging of the rat intestinal mucosa. II. Morphological, enzyme histochemical and disc electrophoretic aspects of the aging of the small intestinal mucosa. Mech Ageing Dev. 1978 ; 7 (3). 217-226 (Pubitemid 8262808)
133. Tallaksen CME, Sande A, Bøhmer T, Bell H, Karlsen J. Kinetic of thiamin and thiamin phosphate esters in human blood, plasma and urine after 50 mg intravenously or orally. Eur J Clin Pharmacol. 1993 ; 44 (1). 73-78 (Pubitemid 23030312)
134. Friedman TE, Kmieckiak TC, Keegan PK, Sheft BB. The absorption, destruction, and excretion of orally administered thiamine by human subjects. Gastroenterology. 1948 ; 11 (1). 100-114
135. Morrison AB, Campbell JA. Vitamin absorption studies. I. Factors influencing the excretion of oral test doses of thiamine and riboflavin by human subjects. J Nutr. 1960 ; 72: 435-440
136. Nichols HK, Basu TK. Thiamine status of the elderly: dietary intake and thiamine pyrophosphate response. J Am Coll Nutr. 1994 ; 13 (1). 57-61 (Pubitemid 24037982)
137. Baker H, Frank O, Jaslow SP. Oral versus intramuscular vitamin supplementation for hypovitaminosis in the elderly. J Am Geriatr Soc. 1980 ; 28 (1). 42-45 (Pubitemid 10207692)
138. Sasaki T, Yukizane T, Atsuta H, et al. A case of thiamine deficiency with psychotic symptoms-blood concentration of thiamine and response to therapy [in Japanese]. Seishin Shinkeigaku Zasshi. 2010 ; 112 (2). 97-110